Macro-Albumon (Human Albumin As Macroaggregates)

Human albumin in Macro-Albumon increases oncotic pressure within the vascular compartment. By retaining water inside blood vessels, it expands plasma volume, improves cardiac preload, and enhances tissue perfusion. Albumin also binds various endogenous substances, contributing to its stabilizing effect on circulatory dynamics.

The dosage of Macro-Albumon is individualized. The prescribing clinician determines the volume and rate of infusion based on the patient’s clinical condition, degree of fluid loss, and response to therapy. No fixed regimen is provided in public information.

Safety data for Macro-Albumon in pregnancy or lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Macro-Albumon, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Compared with synthetic colloids such as hydroxyethyl starch, Macro-Albumon (human albumin) is a natural protein that offers oncotic support with a lower risk of renal dysfunction. Crystalloid solutions provide less oncotic effect and require larger volumes, while albumin offers efficient plasma expansion with fewer electrolyte disturbances.

Macro-Albumon must be stored at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the product in its original packaging until use to maintain sterility and stability.

Macro-Albumon is administered intravenously by slow infusion, typically through a dedicated line. The infusion rate is adjusted according to the patient’s hemodynamic response and clinical guidelines, with continuous monitoring of vital signs throughout the procedure.

Serious risks include anaphylactic reactions, severe volume overload leading to pulmonary edema, hemolysis, and rare infections transmitted through the biologic product. Prompt recognition and management of these events are essential.

Macro-Albumon is contraindicated in patients with known hypersensitivity to human albumin or any component of the formulation. Caution is advised for individuals with uncontrolled heart failure, severe renal impairment, or active infection, where volume expansion may pose additional risks.